These variable cardiovascular and kidney benefits may be attributable to differences in trial conduct or to the medicines or their degradation products potentially having favorable effects with human-based, but not exendin-based, GLP-1 RAs in T2D.13,26. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.